Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 110 participants.
Also called NCT02422888
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Sponsor
- Registry
-
NCT02422888 -
2014-005363-33
-
- Other papers using this trial's data
- Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel
- Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Unknown status
Technical summary
Registry record NCT02422888. Randomized; no masking; primary purpose treatment. Start 2015-05 (actual); primary completion 2017-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor
- Acronym
- REDUCE-MVI
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Prasugrel
- Lead sponsor
- Amsterdam UMC, location VUmc
- Collaborator
- Erasmus Medical Center
- Collaborator
- Hospital San Carlos, Madrid
- Collaborator
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Collaborator
- University Medical Center Nijmegen
Record details
- Record id
cardio:ct-nct02422888- Content hash
639f1d128ef807c41b667eb2e12e191f301652781c42a879c84fbc385786ef89